CMS Initiates Medicare Review for EBR’s WiSE Cardiac Device
EBR Systems has secured a significant regulatory milestone as the US Centers for Medicare & Medicaid Services (CMS) initiates a National Coverage Determination (NCD) for its WiSE wireless cardiac pacing system, aiming for approval by early 2027.
- CMS launches expedited NCD process for WiSE system
- EBR first in CMS TCET program for breakthrough devices
- FDA approval and CMS payment programs already secured
- NCD decision could expand Medicare access nationwide
- Over 39 hospital contracts signed at $63,300 price point
CMS Accelerates Medicare Coverage Review
EBR Systems (ASX:EBR) has achieved a pivotal regulatory advance with the US Centers for Medicare & Medicaid Services (CMS) formally initiating a National Coverage Determination (NCD) process for its WiSE System, a wireless leadless left ventricular endocardial pacing device. This move marks a major step toward establishing uniform Medicare coverage across the United States, potentially broadening patient access and supporting EBR’s commercial ambitions.
The WiSE System’s inclusion in CMS’s Transitional Coverage for Emerging Technologies (TCET) program is notable, EBR was the first company selected for this pathway approximately 18 months ago. The TCET program expedites Medicare evaluation for FDA-designated Breakthrough Devices, slashing the typical multi-year coverage timeline to an anticipated decision by early 2027. Without TCET, national Medicare coverage often takes over five years to secure.
Building on FDA Approval and Payment Programs
The WiSE System earned FDA approval in April 2025 and has since gained CMS approval for New Technology Add-on Payment (NTAP) and Transitional Pass-Through (TPT) payment programs effective from October 2025. Both inpatient and outpatient procedures are reimbursed at a selling price of US$63,300, a pricing framework already underpinning EBR’s commercial contracts. The company has inked more than 39 agreements with individual hospitals and major health systems, setting the stage for broader adoption.
Medicare’s NCD process involves a national coverage analysis to determine if a technology is “reasonable and necessary” for beneficiaries, primarily those aged 65 and over or with specific disabilities. EBR’s NCD request targets heart failure patients eligible for cardiac resynchronization therapy (CRT) who were previously considered untreatable or high-risk for conventional upgrade procedures.
Regulatory Timeline and Market Implications
CMS’s published timeline sets a public comment period from June to July 2026, with a proposed decision memo due by December 2026, followed by a final NCD expected in March 2027. This accelerated schedule contrasts sharply with the usual multi-year wait for national Medicare coverage decisions, reflecting the impact of the TCET program on breakthrough medical technologies.
EBR’s progress dovetails with its recent commercial momentum, including multi-hospital purchasing agreements that have expanded its US footprint. The national coverage framework, if positive, would remove regional reimbursement disparities and encourage wider adoption by healthcare providers, potentially accelerating revenue growth and market penetration for the WiSE System.
Bottom Line?
The CMS NCD process positions EBR’s WiSE System for a potentially transformative Medicare coverage decision by early 2027, a critical catalyst for US market expansion.
Questions in the middle?
- Will CMS’s final NCD decision fully endorse Medicare coverage for WiSE, and on what terms?
- How will expanded Medicare access influence hospital adoption rates beyond existing contracts?
- What competitive pressures might emerge as WiSE gains broader reimbursement and commercial traction?
